Published online before print February 27, 2003, doi: 10.1161/01.RES.0000064502.47539.6D
© 2003 American Heart Association, Inc.
Molecular Medicine |
Endothelial Cells Secrete Triglyceride Lipase and Phospholipase Activities in Response to Cytokines as a Result of Endothelial Lipase
From the Department of Medicine, University of Pennsylvania, Philadelphia, Pa.
Correspondence to Daniel J. Rader, MD, University of Pennsylvania Medical Center, 654 BRB II/III, 421 Curie Blvd, Philadelphia, PA 19104-6100. E-mail rader{at}mail.med.upenn.edu
 |
Abstract |
|---|
 Top Abstract IntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The endothelium interacts extensively with lipids and lipoproteins, but there are very few data regarding the ability of endothelial cells to secrete lipases. In this study, we investigated the ability of endothelial cells to secrete the triglyceride lipase and phospholipase activities characteristic of endothelial lipase (EL), a recently described member of the triglyceride lipase gene family. No lipase activities were detected under basal conditions, but treatment with cytokines significantly stimulated the expression of both activities. Using antibodies to EL, we determined that both activities were primarily a result of this enzyme. In addition to the increase in lipolytic activity, cytokine treatment was demonstrated to substantially upregulate EL protein and EL mRNA in a dose-dependent manner. Cytokines did not change EL mRNA stability. Both new protein synthesis and activation of NF-
B influenced the induction of EL by cytokines, suggesting that multiple pathways contribute to this process. The upregulation of EL by cytokines is in sharp contrast to the downregulation by cytokines of the other two major members of this gene family, lipoprotein lipase and hepatic lipase, and has implications for the physiological role of EL in inflammatory conditions and its potential role in the modulation of lipoprotein metabolism during inflammatory conditions, including atherosclerosis.
Key Words: lipase • inflammation • endothelium • cytokines • nuclear factor-B
|
Introduction |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
The endothelium interacts with a variety of extracellular lipids in the blood, including triglycerides and phospholipids carried within lipoproteins. Two members of the triglyceride lipase gene family, lipoprotein lipase (LPL) and hepatic lipase (HL), are synthesized by parenchymal cells but function at the endothelial surface, where they are bound to heparan sulfate proteoglycans.1 LPL plays a central role in energy homeostasis and lipoprotein metabolism by hydrolyzing lipoprotein triglycerides in adipose tissue and muscle.1 It is synthesized by underlying adipocytes and myocytes and is transported to the luminal surface of capillary endothelium, where it is active. HL is another member of the gene family that plays a role in lipoprotein metabolism by hydrolyzing triglycerides and phospholipids of remnant lipoproteins and HDL in the liver.2 HL exists on the surface of hepatocytes3 and is also transported to the endothelial surface of the sinusoids, where it interacts with lipoproteins. In addition, HL is found on endothelium in the adrenals and gonads.4
Neither LPL nor HL is synthesized by endothelial cells. Indeed, there has been relatively little evidence that endothelial cells themselves synthesize any enzymes with lipolytic activity. A recent report indicated that human umbilical vein endothelial cells (HUVECs) secreted an enzyme that had the ability to degrade lysolecithin but expressed relatively little phospholipase and no triglyceride lipase activity under the conditions tested.5 We and others recently reported the discovery of a new member of the triglyceride lipase gene family,6,7 and in contrast to the case of LPL or HL, its mRNA was demonstrated in endothelial cells. The enzyme was named endothelial lipase (EL) because of this unique characteristic, although its expression is not restricted to endothelial cells.8 Previous work showed that transient expression of the EL cDNA led to secretion of phospholipase activity,6,7 and we subsequently demonstrated that EL also has significant triglyceride lipase activity.9 Overexpression of human EL in mice significantly reduced HDL cholesterol levels,6 and our recent data show that acute inhibition of EL results in increased HDL cholesterol levels in vivo.10 Therefore, EL expression appears to be an important modulator of HDL metabolism.
EL mRNA has also been shown to be upregulated by inflammatory cytokines in HUVECs.11 Despite these findings, expression of native lipolytic activity by endothelial cells because of secretion of EL has never been reported. In this report, we demonstrate that although endothelial cells do not secrete triglyceride lipase and phospholipase activity under basal conditions, stimulation with inflammatory cytokines results in the stimulation of the secretion of these lipase activities, both of which are inhibited by an antibody to EL. Both EL protein and EL mRNA were found to be significantly upregulated by cytokines in HUVECs and two other endothelial cell types. Therefore, endothelial cells express both phospholipase and triglyceride lipase activities in response to cytokines that is a result of upregulation of EL.
|
Materials and Methods |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Human dermal microvascular endothelial cells (HDMVECs), human uterine microvascular endothelial cells (HUtMVECs), cell culture medium EGM-2 BulletKit CC-3162 (used for HUVECs), and EGM-2 MV BulletKit CC-3147 (used for MVECs) were purchased from Clonetics. Recombinant human tissue necrosis factor (TNF)-
and recombinant human interleukin (IL)-1ß were from R&D Systems. Heparin was purchased from Sigma. Actinomycin D and cycloheximide were purchased from Calbiochem.
Antibodies
A rabbit polyclonal antibody against human (h) EL generated to a peptide in the N-terminal region was described elsewhere6 and is referred to below as the anti-hEL peptide antibody. A second rabbit polyclonal antibody to hEL was raised using an adenoviral vector encoding hEL6 as follows: 5x1012 viral particles were injected into a New Zealand White rabbit (Hare-Marland, Princeton, NJ) via the ear vein. Sera were obtained at various intervals for analysis of antibody to hEL. Six months after injection, the rabbit was anesthetized and exsanguinated. Serum was prepared and stored at -80°C. IgG fractions were purified by use of an ImmunoPure IgG (Protein A) purification kit (Pierce). This antibody is referred to below as anti-AdhEL.
Cell Culture
HUVECs were isolated from human umbilical cords as described.12 Passages 2 through 5 were used in the experiments. The HUVECs had typical features of cobblestone morphology. HDMVECs and HUtMVECs were cultured as specified by Clonetics.
Treatment of HUVECs With IL-1ß and TNF-
HUVECs were seeded into 60-mm culture plates (Falcon) at a density of 1x106 cells and treated in serum-free culture medium containing IL-1ß (0 to 3 ng/mL) or TNF- (0 to 10 ng/mL) for 24 hours or with IL-1ß (1 ng/mL) or TNF- (10 ng/mL) for up to 72 hours.13 Thirty minutes before harvest, heparin stock solution (20 mg/mL) was added to bring the final heparin concentration to 0.4 mg/mL. The culture medium was collected, centrifuged at 3000g for 10 minutes to remove cell debris, and stored in 0.5-mL aliquots at -80°C until use.
Western Blotting
Culture medium and Laemmli sample buffer were mixed 1:1 (vol/vol) and heated at 85°C for 10 minutes. The samples were size-fractionated with SDS-PAGE (precast 10% polyacrylamide gels; FMC) and transferred to Hybond-P (PVDF) membrane (Amersham Pharmacia Biotech). The anti-hEL peptide antibody antiserum, used as the primary antibody, was diluted 1:3000, and the secondary horseradish peroxidase–conjugated goat anti-rabbit IgG (Jackson Laboratories) was diluted 1:3000 from a 50% glycerol stock (final dilution, 1:6000). Detection was carried out by the ECL protocol (Amersham Pharmacia Biotech) according to the manufacturer’s instructions. Chemiluminescence signals were detected on x-ray films and quantified by densitometry.
Northern Blotting
Total cellular RNA was extracted from cells with TRIzol (Gibco BRL) according to the manufacturer’s protocol. RNA quantification was performed by spectrophotometry, and the integrity of RNA was analyzed by electrophoresis of 5 µg of total RNA on a 1.5% agarose gel stained with ethidium bromide. Total RNA (1 to 5 µg/lane) was electrophoresed through a 1.2% agarose gel containing formaldehyde and blotted to a Hybond-N membrane by capillary transfer. Probe synthesis, hybridization, and detection methods for all Northern blots were performed according to Roche Molecular Biochemical specifications for digoxigenin-labeled probes. A pPCR-ScriptTM Amp SK(+) vector containing the hEL polymerase chain reaction (PCR)-amplified 1.5-kb product was linearized with HindIII and used as a template for digoxigenin-labeled riboprobe synthesis; a pGEM-T vector containing the ß-actin PCR-amplified 100-bp product was linearized with SpeI and used as a template for digoxigenin-labeled riboprobe synthesis. Membranes were washed twice at room temperature in 2xSSC with 0.1% SDS for 5 minutes, followed by two washes in 0.1xSSC with 0.1% SDS at 68°C for 15 minutes, followed by incubation for 1 hour at 68°C in DIG Easy Hyb granules before immunological detection. Chemiluminescence signals derived from hybridized probes were detected on x-ray films with DIG luminescence detection kits (Roche Molecular Biochemicals) and quantified by densitometry.
Real-Time PCR
One microgram of total RNA was converted into cDNA using the SuperScript first-strand synthesis system for reverse-transcription PCR (Roche Molecular Biochemicals). Reverse-transcription PCR was performed in an ABI Prism 7700 Sequence Detector System (PE Applied Biosystems). PCR primers were designed by use of Primer Express software according to the recommendations of Applied Biosystems. The sequences of primers and TaqMan probes for EL and ß-actin genes were as follows: the EL gene, 5'-ACAACCTGTGGAAGGAGTTTCG-3' (forward primer), 5'-CGGATGCGCCTGATATTCA-3' (reverse primer), and 5'-FAM-CTGTCTCAACCCCGCAACCCCGGA-TAMRA-3' (TaqMan probe); the ß-actin gene, 5'-CTCCTCCTGAGCGCAAGTACTC-3' (forward primer), 5'-TCGTCATACTCCTGCTTGCTGAT-3' (reverse primer), and 5'-FAM-CCATCCTGGCCTCGCTGTCCA-TAMRA-3' (TaqMan probe). The relative amounts of all mRNAs were calculated by the comparative CT method.14 ß-Actin mRNA was used as the invariant control for all studies.
Immunoprecipitation
Pooled culture media were incubated with rabbit anti-AdhEL IgG and control rabbit IgG at 4°C for 1 hour. The anti-hEL peptide antibody, although useful for Western blotting, does not immunoprecipitate EL well. Protein A-Sepharose (Gibco BRL) was added to each sample, and they were incubated for an additional hour. After spinning to pellet the Sepharose beads, the supernatant was used for the lipase activity assay. Control media were diluted with a volume of PBS equivalent to that added to the other samples and were incubated similarly.
Lipase Activity Assays
Both triglyceride lipase and phospholipase activities were assayed as previously described.9
|
Results |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
Triglyceride Lipase and Phospholipase Activity Secreted by Endothelial Cells in Response to Cytokines Is Primarily a Result of Endothelial Lipase
Triglyceride lipase and phospholipase activities were determined in conditioned media from HUVECs treated with IL-1ß and TNF-
and compared with media harvested from a parallel set of cells not treated with cytokines. The levels of both lipase activities under basal conditions were similar to the background for the assays. Both lipase activities were significantly increased after IL-1ß or TNF- treatment (Figure 1). To determine whether these activities were caused by EL, we performed several experiments. Consistent with our observation that EL triglyceride lipase and phospholipase activities are inhibited by 1 mol/L NaCl (like LPL and unlike HL),9 we found that the lipase activities in the cytokine-treated HUVEC media were inhibited completely by 1 mol/L NaCl (data not shown). We also tested whether immunoprecipitation with anti-AdhEL antibody to EL affected the lipase activities. Preliminary studies using conditioned media containing human EL showed that anti-AdhEL IgG significantly reduced the triglyceride lipase and phospholipase activities, whereas control rabbit IgG did not affect lipase activity. This antibody did not inhibit LPL and HL enzymatic activities in similar experiments. As shown in Figure 2, this antibody cleared 75% of triglyceride lipase activity and 75% of phospholipase activity from the IL-1ß HUVEC conditioned media and 88% of triglyceride lipase activity and 57% of phospholipase activity from the TNF-–treated HUVEC conditioned media compared with control antibody. This indicates that the triglyceride lipase and phospholipase activities secreted by HUVECs in response to cytokines are caused primarily by EL.
|
2 nmol/mL-hr.
|
EL Protein Secretion Is Stimulated by Cytokines
EL protein in HUVEC culture medium was detected by Western blotting using a rabbit anti-hEL peptide antibody as previously described.6 Media were harvested after the addition of heparin to release EL bound to the cell surface. Immunoblotting of media from HUVECs harvested at various time points after the change of media revealed two major EL bands of 68 kDa and 40 kDa (Figure 3A). In untreated HUVECs, EL protein accumulated progressively in the media over 72 hours of incubation. In cells treated with IL-1ß (Figure 3B), expression of EL protein was substantially increased compared with untreated cells. The increase in EL protein caused by IL-1ß was apparent by 12 hours, and the difference between IL-1ß–treated and untreated cells increased over the 72 hours. In cells treated with TNF- (Figure 3C), a similar response was seen. Thus, both TNF- and IL-1ß treatment resulted in substantial increases in EL protein in the media, consistent with the increase in lipase activities induced by these cytokines.
|
Cytokine-Induced EL Expression Is Dose Dependent
HUVECs were treated with increasing concentrations of IL-1ß, ranging from 1 pg/mL to 3 ng/mL. Dose-dependent increases in secreted EL protein (Figure 4A) and EL mRNA (Figure 4B) were noted. The relative increases in EL protein and mRNA were greater in the middle dose range (30 pg/mL–1 ng/mL) and plateaued at higher concentrations of IL-1ß. Increasing concentrations of TNF- also resulted in dose-dependent increases in EL protein (Figure 4C) and EL mRNA (Figure 4D).
|
EL contains several of the consensus heparin binding sequences that have been demonstrated in LPL and HL. To determine whether treatment with TNF- or IL-1ß for 24 hours increased the amount of EL protein that remained bound to cells, we removed the medium for analysis, then washed the cells and added fresh medium containing 10 U/mL heparin to dissociate cell surface–bound EL. After 30 minutes of incubation with heparin, the media were harvested and analyzed for EL protein by Western blotting. As above, both the 68-kDa and 40-kDa forms of EL were detected abundantly in the preheparin culture medium, but primarily the 68-kDa form of EL was detected in the heparin-released medium and was significantly increased by cytokine treatment. This suggests that the 40-kDa form, which probably results from proteolytic cleavage of the 68-kDa form, may have less affinity for the cell surface. There was a dose-dependent increase in the 68-kDa form of EL in both IL-1ß–treated and TNF-–treated cells compared with untreated cells (see online Figure, available in the online data supplement at http://www.circresaha.org).
EL Expression Is Also Upregulated by Cytokines in Microvascular Endothelial Cells
To determine whether other types of endothelial cells also respond to cytokines by upregulating EL expression, we selected two different types of microvascular endothelial cells for additional studies. HDMVECs, HUtMVECs, and HUVECs were treated with IL-1ß (1 ng/mL) and TNF- (10 ng/mL) for 24 hours. The media were analyzed by Western blotting with the anti-hEL peptide antibody. Both IL-1ß and TNF- significantly increased the amount of EL protein in the media of the two types of microvascular endothelial cells (Figure 5A). There was also an increase in EL mRNA for both IL-1ß–treated and TNF-–treated cells (Figure 5B).
|
Cytokines Do Not Alter EL mRNA Stability
To determine whether cytokines affected the steady-state level of EL mRNA by increasing its stability, we measured EL mRNA using real-time PCR in the presence of actinomycin D (5 µg/mL) in HUVECs. The EL mRNA half-life in HUVECs did not change after treatment with IL-1ß (1 ng/mL) or TNF- (10 ng/mL) (Figure 6). Thus, the cytokine-induced increase in the level of EL mRNAs in endothelial cells was not the result of an increase in the stability of the mRNA. Of note, the use of actinomycin D in this study does not exclude the possibility that it inhibits mRNAs or proteins downstream that influence EL mRNA stability. The cytokine effect is presumably transcriptional, but using EL promoter-reporter gene constructs, we were unable to detect cytokine-responsive elements with up to 3 kb of EL promoter (data not shown).
|
Induction of EL Expression by Cytokines Is Partly Dependent on Protein Synthesis
To determine whether the increase in EL mRNA required protein synthesis, we pretreated HUVECs with the protein synthesis inhibitor cycloheximide at a concentration of 5 µg/mL. Cycloheximide alone had little effect on EL mRNA abundance at this dose. However, pretreatment with cycloheximide markedly blunted the ability of cytokines to induce EL mRNA expression (Figure 7A), indicating that the effect of cytokines on EL in HUVECs depends at least partly on new protein synthesis. VCAM-1 mRNA induced by cytokines was moderately decreased after cycloheximide treatment (Figure 7B), which is consistent with a previous report.15
|
NF-B Pathway Is Involved in the Induction of EL mRNA by Cytokines
To define further the signaling pathway(s) responsible for upregulation of EL mRNA by cytokines, we treated HUVECs with agents that antagonize the transcriptional effects of cytokines on gene expression: SN50 (an NF-B pathway inhibitor),16 SB 20358 (a p38 MARK–specific inhibitor),17 PD 98059 (a p42/44 MARK–specific inhibitor),18 GF 109203X (a PKC inhibitor),19 and D609 (a PC-PLC–activity inhibitor).20 None of these compounds except SN50 had any effect on the induction of EL expression by cytokines. At 50 µg/mL for 24 h, SN50 diminished but did not abolish EL mRNA expression induced by cytokines (Figure 8A). The upregulation of VCAM-1 mRNA, which is known to be upregulated via the NF-B pathway induced by cytokines, was abolished after SN50 treatment (Figure 8B).
|
|
Discussion |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
This report is the first to document that endothelial cells secrete both triglyceride lipase and phospholipase activities in response to the inflammatory cytokines IL-1ß and TNF-
. Both lipolytic activities were specifically inhibited by antibody to endothelial lipase. Western blotting confirmed the cytokine-stimulated secretion of EL protein. This regulation appears to be at least in part at the level of mRNA abundance, because EL mRNA levels were increased, consistent with a recent report.11 These results indicate that endothelial cells secrete both triglyceride lipase and phospholipase activity in response to cytokines and that EL is the major source of both lipase activities.
We explored various mechanisms that might be responsible for the effect of IL-1ß and TNF- on the induction of the EL mRNA expression. New protein synthesis was necessary for effective upregulation of EL mRNA by cytokines. Cytokines had little effect on EL mRNA half-life, which suggests that they probably increase the rate of transcription of the EL gene. Therefore, we examined the effects of agents known to modulate transcriptional responses of IL-1ß and TNF-. Of these agents, only SN50, an inhibitor of the NF-B pathway, diminished upregulation of EL mRNA expression by cytokines, suggesting that this pathway might be involved. NF-B proteins are known to play a central role in endothelial cell activation by cytokines. This pathway is rapidly activated by cytokines, with a peak at 30 minutes. Although the kinetics of EL induction in endothelial cells by cytokines is not congruent with the kinetics of change of NF-B, we speculate that NF-B might be involved in initiating the effect of cytokines, perhaps via induction of other factors that ultimately mediate the upregulation of EL. Also, a short exposure (2 hours) of endothelial cells to cytokines was sufficient to elicit the late induction of EL mRNA (unpublished data). In experiments not presented here, we examined the effect of cytokines on reporter gene expression under the control of 3 kb of the 5' flanking sequence of the EL gene (which contains two consensus NF-B binding sites) in transient transfection assays of HUVECs. No significant change of reporter gene expression was observed. The lack of effect of cytokines on this construct suggests that cytokines exert their transcriptional effects on EL, either directly or indirectly, through DNA elements outside the cloned 3 kb of 5' flanking sequence.
The upregulation of EL by cytokines is in distinct contrast to the two other major members of this gene family, LPL and HL, both of which are downregulated by inflammatory cytokines. LPL activity in vivo is reduced in inflammatory conditions,1,21 and inflammatory cytokines downregulate LPL expression in vitro.21 LPL hydrolyzes triglycerides in triglyceride-rich lipoproteins, generating free fatty acids for energy use by skeletal and cardiac muscle and for conversion to triglyceride and storage by adipocytes, thus playing an important role in energy homeostasis and catabolism of triglyceride-rich lipoproteins.22 Macrophages also express LPL, the activity of which may provide a source of fatty acids for energy utilization.23 The downregulation of LPL by inflammatory cytokines is thought to be at least one explanation for the hypertriglyceridemia associated with inflammatory conditions.24 Although there is less information about HL, administration of lipopolysaccharide and IL-1ß to hamsters also resulted in marked downregulation of HL expression.25 HL hydrolyzes triglycerides in remnant lipoproteins, and its downregulation in inflammation could also contribute to elevated triglycerides in inflammation. During acute inflammation, energy needs are increased. It is possible that EL is upregulated in endothelial cells at local sites of inflammation as a way of generating fatty acids derived from lipoproteins to be utilized by local tissues (including possibly the endothelial cells themselves) as an alternative energy source. Endothelial cells abundantly express CD36, which directly binds lipoproteins26 and has an important role in cellular uptake of fatty acids.27,28 Furthermore, other tissues that express EL, such as the thyroid, the gonads, and even macrophages,29 might utilize fatty acids generated from lipoprotein triglycerides and phospholipids by EL for energy. Therefore, it is reasonable that, under certain systemic inflammatory conditions, the coordinated downregulation of LPL and HL and upregulation of EL is a result of a physiological need to direct lipoprotein-derived fatty acids away from skeletal muscle, adipose tissue, and liver and toward local sites of inflammation at which EL is being expressed.
Acute inflammatory states, such as sepsis, are associated with profoundly reduced HDL cholesterol levels.30,31 Furthermore, chronic inflammatory states, such as rheumatoid arthritis and systemic lupus, are also associated with reduced levels of HDL cholesterol.32 As noted above, HL, which has a known role in HDL metabolism, is downregulated by inflammation,25 an effect that would normally be expected to increase, not decrease, HDL cholesterol levels. We previously demonstrated that overexpression of EL in mice markedly reduced plasma levels of HDL cholesterol and apolipoprotein A-I.7 The results presented here suggest the possibility that inflammation-induced upregulation of EL could be a causal factor in the reduced HDL cholesterol levels seen in inflammatory conditions. Atherosclerosis itself is increasingly recognized as a chronic inflammatory condition.33 Epidemiological studies have indicated that systemic markers of inflammation are associated with coronary events.34 Pathological studies have provided substantial evidence for inflammation within the atherosclerotic plaque.35 Our demonstration that inflammatory cytokines upregulate the endothelial expression of EL suggests that EL could be upregulated at the site of atherosclerotic lesions. It is intriguing to speculate that the inflammation associated with atherosclerosis, by upregulating local EL expression, may itself influence systemic lipoprotein metabolism.
In summary, endothelial cells secrete both triglyceride lipase and phospholipase activities in response to cytokines that is primarily a result of upregulation of EL. Both new protein synthesis and the NF-B pathway mediate induction of EL expression. The upregulation of EL by cytokines is in sharp contrast to downregulation of the other two major members of this gene family, LPL and HL, and has implications for the physiological role of EL in inflammatory conditions and its potential role in the modulation of lipoprotein metabolism during inflammatory conditions, including atherosclerosis.
|
Acknowledgments |
|---|
This study was supported in part by NIH grants HL-55323 (to D.J.R.) and HL-55756 (to J.M.G.). D.J.R. is an Established Investigator of the American Heart Association, a recipient of the Burroughs Wellcome Clinical Scientist Award for Translational Research, and a recipient of a Doris Duke Distinguished Clinical Scientist Award. We are indebted to Joseph Manupello and Anthony Secreto for excellent technical assistance and Dr Douglas Cines for helpful discussions.
Received October 17, 2000; revision received August 16, 2002; accepted February 13, 2003.
|
References |
|---|
|
TopAbstractIntroductionMaterials and MethodsResultsDiscussionReferences |
|---|
1. Goldberg IJ. Lipoprotein lipase and lipolysis: central roles in lipoprotein metabolism and atherogenesis. J Lipid Res. 1996; 37: 693–707.[Abstract]
2. Santamarina-Fojo S, Haudenschild C, Amar M. The role of hepatic lipase in lipoprotein metabolism and atherosclerosis. Curr Opin Lipidol. 1998; 9: 211–219.[CrossRef][Medline] [Order article via Infotrieve]
3. Sanan DA, Fan J, Bensadoun A, Taylor JM. Hepatic lipase is abundant on both hepatocyte and endothelial cell surfaces in the liver. J Lipid Res. 1997; 38: 1002–1013.[Abstract]
4. Jansen H, De Greef WJ. Heparin-releasable lipase activity of rat adrenals, ovaries and testes. Biochem J. 1981; 196: 739–745.[Medline] [Order article via Infotrieve]
5. Tosti E, Dahl L, Endresen MJ, Henriksen T. Endothelial degradation of extracellular lyso-phosphatidylcholine. Scand J Clin Lab Invest. 1999; 59: 249–257.[CrossRef][Medline] [Order article via Infotrieve]
6. Jaye M, Lynch KJ, Krawiec J, Marchadier D, Maugeais C, Doan K, South V, Amin D, Perrone M, Rader DJ. A novel endothelial-derived lipase that modulates HDL metabolism. Nat Genet. 1999; 21: 424–428.[CrossRef][Medline] [Order article via Infotrieve]
7. Hirata K, Dichek HL, Cioffi JA, Choi SY, Leeper NJ, Quintana L, Kronmal GS, Cooper AD, Quertermous T. Cloning of a unique lipase from endothelial cells extends the lipase gene family. J Biol Chem. 1999; 274: 14170–14175.
8. Jin W, Marchadier D, Rader DJ. Lipases and HDL metabolism. Trends Endocrinol Metab. 2002; 13: 174–178.[CrossRef][Medline] [Order article via Infotrieve]
9. McCoy MG, Sun GS, Marchadier D, Maugeais C, Glick JM, Rader DJ. Characterization of the lipolytic activity of endothelial lipase. J Lipid Res. 2002; 43: 921–929.
10. Jin W, Millar JS, Broedl U, Glick JM, Rader DJ. Inhibition of endothelial lipase causes increased HDL cholesterol levels in vivo. J Clin Invest. 2003; 111: 357–362.[CrossRef][Medline] [Order article via Infotrieve]
11. Hirata K, Ishida T, Matsushita H, Tsao PS, Quertermous T. Regulated expression of endothelial cell-derived lipase. Biochem Biophys Res Commun. 2000; 272: 90–93.[CrossRef][Medline] [Order article via Infotrieve]
12. Gimbrone MA Jr. Culture of vascular endothelium. Prog Hemost Thromb. 1976; 3: 1–28.[Medline] [Order article via Infotrieve]
13. Marx N, Sukhova GK, Collins T, Libby P, Plutzky J. PPAR- activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation. 1999; 99: 3125–3131.
14. Liang G, Yang J, Horton JD, Hammer RE, Goldstein JL, Brown MS. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002; 277: 9520–9528.
15. Neish AS, Read MA, Thanos D, Pine R, Maniatis T, Collins T. Endothelial interferon regulatory factor 1 cooperates with NF-B as a transcriptional activator of vascular cell adhesion molecule 1. Mol Cell Biol. 1995; 15: 2558–2569.[Abstract]
16. Lin YZ, Yao SY, Veach RA, Torgerson TR, Hawiger J. Inhibition of nuclear translocation of transcription factor NF-B by a synthetic peptide containing a cell membrane-permeable motif and nuclear localization sequence. J Biol Chem. 1995; 270: 14255–14258.
17. Tong L, Pav S, White DM, Rogers S, Crane KM, Cywin CL, Brown ML, Pargellis CA. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nat Struct Biol. 1997; 4: 311–316.[CrossRef][Medline] [Order article via Infotrieve]
18. Langlois WJ, Sasaoka T, Saltiel AR, Olefsky JM. Negative feedback regulation and desensitization of insulin- and epidermal growth factor-stimulated p21ras activation. J Biol Chem. 1995; 270: 25320–25323.
19. Toullec D, Pianetti P, Coste H, Bellevergue P, Grand-Perret T, Ajakane M, Baudet V, Boissin P, Boursier E, Loriolle F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991; 266: 15771–15781.
20. Goebeler M, Gillitzer R, Kilian K, Utzel K, Brocker EB, Rapp UR, Ludwig S. Multiple signaling pathways regulate NF-B-dependent transcription of the monocyte chemoattractant protein-1 gene in primary endothelial cells. Blood. 2001; 97: 46–55.
21. Feingold KR, Marshall M, Gulli R, Moser AH, Grunfeld C. Effect of endotoxin and cytokines on lipoprotein lipase activity in mice. Arterioscler Thromb. 1994; 14: 1866–1872.
22. Zechner R. The tissue-specific expression of lipoprotein lipase: implications for energy and lipoprotein metabolism. Curr Opin Lipidol. 1997; 8: 77–88.[CrossRef][Medline] [Order article via Infotrieve]
23. Yin B, Loike JD, Kako Y, Weinstock PH, Breslow JL, Silverstein SC, Goldberg IJ. Lipoprotein lipase regulates Fc receptor-mediated phagocytosis by macrophages maintained in glucose-deficient medium. J Clin Invest. 1997; 100: 649–657.[Medline] [Order article via Infotrieve]
24. Grunfeld C, Feingold KR. Regulation of lipid metabolism by cytokines during host defense. Nutrition. 1996; 12: S24–S26.[Medline] [Order article via Infotrieve]
25. Feingold KR, Memon RA, Moser AH, Shigenaga JK, Grunfeld C. Endotoxin and interleukin-1 decrease hepatic lipase mRNA levels. Atherosclerosis. 1999; 142: 379–387.[CrossRef][Medline] [Order article via Infotrieve]
26. Calvo D, Gomez-Coronado D, Suarez Y, Lasuncion MA, Vega MA. Human CD36 is a high affinity receptor for the native lipoproteins HDL, LDL, and VLDL. J Lipid Res. 1998; 39: 777–788.
27. Febbraio M, Abumrad NA, Hajjar DP, Sharma K, Cheng W, Pearce SF, Silverstein RL. A null mutation in murine CD36 reveals an important role in fatty acid and lipoprotein metabolism. J Biol Chem. 1999; 274: 19055–19062.
28. Aitman TJ, Glazier AM, Wallace CA, Cooper LD, Norsworthy PJ, Wahid FN, Al Majali KM, Trembling PM, Mann CJ, Shoulders CC, Graf D, St Lezin E, Kurtz TW, Kren V, Pravenec M, Ibrahimi A, Abumrad NA, Stanton LW, Scott J. Identification of Cd36 (Fat) as an insulin-resistance gene causing defective fatty acid and glucose metabolism in hypertensive rats. Nat Genet. 1999; 21: 76–83.[CrossRef][Medline] [Order article via Infotrieve]
29. Rader DJ, Jaye M. Endothelial lipase: a new member of the triglyceride lipase gene family. Curr Opin Lipidol. 2000; 11: 141–147.[CrossRef][Medline] [Order article via Infotrieve]
30. Bausserman LL, Bernier DN, McAdam KP, Herbert PN. Serum amyloid A and high density lipoproteins during the acute phase response. Eur J Clin Invest. 1988; 18: 619–626.[Medline] [Order article via Infotrieve]
31. Barter P. Effects of inflammation on high-density lipoproteins. Arterioscler Thromb Vasc Biol. 2002; 22: 1062–1063.
32. Rossner S. Further studies on serum lipoproteins in connective tissue diseases. Atherosclerosis. 1978; 31: 93–99.[CrossRef][Medline] [Order article via Infotrieve]
33. Naiki H, Higuchi K, Yonezu T, Hosokawa M, Takeda T. Metabolism of senile amyloid precursor and amyloidogenesis: age-related acceleration of apolipoprotein A-II clearance in the senescence accelerated mouse. Am J Pathol. 1988; 130: 579–587.[Abstract]
34. Rader DJ. Inflammatory markers of coronary risk. N Engl J Med. 2000; 343: 1179–1182.
35. Lee RT, Libby P. The unstable atheroma. Arterioscler Thromb Vasc Biol. 1997; 17: 1859–1867.
This article has been cited by other articles:
 |
|
 |
|
  H. Wiersma, A. Gatti, N. Nijstad, F. Kuipers, and U. J. F. Tietge Hepatic SR-BI, not endothelial lipase, expression determines biliary cholesterol secretion in mice J. Lipid Res., August 1, 2009; 50(8): 1571 - 1580. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. A. Bainbridge, J. M. Roberts, F. von Versen-Hoynck, J. Koch, L. Edmunds, and C. A. Hubel Uric acid attenuates trophoblast invasion and integration into endothelial cell monolayers Am J Physiol Cell Physiol, August 1, 2009; 297(2): C440 - C450. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Otera, T. Ishida, T. Nishiuma, K. Kobayashi, Y. Kotani, T. Yasuda, R. K. Kundu, T. Quertermous, K.-i. Hirata, and Y. Nishimura Targeted inactivation of endothelial lipase attenuates lung allergic inflammation through raising plasma HDL level and inhibiting eosinophil infiltration Am J Physiol Lung Cell Mol Physiol, April 1, 2009; 296(4): L594 - L602. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. O. Badellino, M. L. Wolfe, M. P. Reilly, and D. J. Rader Endothelial Lipase Is Increased In Vivo by Inflammation in Humans Circulation, February 5, 2008; 117(5): 678 - 685. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Qiu and J. S. Hill Atorvastatin decreases lipoprotein lipase and endothelial lipase expression in human THP-1 macrophages J. Lipid Res., October 1, 2007; 48(10): 2112 - 2122. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. Fontaine-Bisson, T. M. Wolever, J.-L. Chiasson, R. Rabasa-Lhoret, P. Maheux, R. G Josse, L. A Leiter, N W. Rodger, E. A Ryan, P. W Connelly, et al. Genetic polymorphisms of tumor necrosis factor-{alpha} modify the association between dietary polyunsaturated fatty acids and fasting HDL-cholesterol and apo A-I concentrations Am. J. Clinical Nutrition, September 1, 2007; 86(3): 768 - 774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Wang, W. Jin, and D. J. Rader Upregulation of Macrophage Endothelial Lipase by Toll-Like Receptors 4 and 3 Modulates Macrophage Interleukin-10 and -12 Production Circ. Res., April 13, 2007; 100(7): 1008 - 1015. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. J. Mitnaul, J. Tian, C. Burton, M.-H. Lam, Y. Zhu, S. H. Olson, J. E. Schneeweis, P. Zuck, S. Pandit, M. Anderson, et al. Fluorogenic substrates for high-throughput measurements of endothelial lipase activity J. Lipid Res., February 1, 2007; 48(2): 472 - 482. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. Qiu, A. C. Ho, W. Yu, and J. S. Hill Suppression of endothelial or lipoprotein lipase in THP-1 macrophages attenuates proinflammatory cytokine secretion J. Lipid Res., February 1, 2007; 48(2): 385 - 394. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-E. Paradis, K. O. Badellino, D. J. Rader, Y. Deshaies, P. Couture, W. R. Archer, N. Bergeron, and B. Lamarche Endothelial lipase is associated with inflammation in humans J. Lipid Res., December 1, 2006; 47(12): 2808 - 2813. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Ahmed, G. Orasanu, V. Nehra, L. Asatryan, D. J. Rader, O. Ziouzenkova, and J. Plutzky High-Density Lipoprotein Hydrolysis by Endothelial Lipase Activates PPAR{alpha}: A Candidate Mechanism for High-Density Lipoprotein-Mediated Repression of Leukocyte Adhesion Circ. Res., March 3, 2006; 98(4): 490 - 498. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. W. S. Ko, A. Paul, K. Ma, L. Li, and L. Chan Endothelial lipase modulates HDL but has no effect on atherosclerosis development in apoE-/- and LDLR-/- mice J. Lipid Res., December 1, 2005; 46(12): 2586 - 2594. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. L. Ruel, B. Lamarche, J.-F. Mauger, K. O. Badellino, J. S. Cohn, M. Marcil, and P. Couture Effect of Fenofibrate on Plasma Lipoprotein Composition and Kinetics in Patients With Complete Hepatic Lipase Deficiency Arterioscler Thromb Vasc Biol, December 1, 2005; 25(12): 2600 - 2607. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. Jin, I. V. Fuki, N. G. Seidah, S. Benjannet, J. M. Glick, and D. J. Rader Proprotein Covertases Are Responsible for Proteolysis and Inactivation of Endothelial Lipase J. Biol. Chem., November 4, 2005; 280(44): 36551 - 36559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Kempe, H. Kestler, A. Lasar, and T. Wirth NF-{kappa}B controls the global pro-inflammatory response in endothelial cells: evidence for the regulation of a pro-atherogenic program Nucleic Acids Res., September 21, 2005; 33(16): 5308 - 5319. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gauster, G. Rechberger, A. Sovic, G. Horl, E. Steyrer, W. Sattler, and S. Frank Endothelial lipase releases saturated and unsaturated fatty acids of high density lipoprotein phosphatidylcholine J. Lipid Res., July 1, 2005; 46(7): 1517 - 1525. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Shimokawa, K.-i. Hirata, T. Ishida, Y. Kojima, N. Inoue, T. Quertermous, and M. Yokoyama Increased expression of endothelial lipase in rat models of hypertension Cardiovasc Res, June 1, 2005; 66(3): 594 - 600. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Gauster, A. Hrzenjak, K. Schick, and S. Frank Endothelial lipase is inactivated upon cleavage by the members of the proprotein convertase family J. Lipid Res., May 1, 2005; 46(5): 977 - 987. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Isoda, S. Sawada, M. Ayaori, T. Matsuki, R. Horai, Y. Kagata, K. Miyazaki, M. Kusuhara, M. Okazaki, O. Matsubara, et al. Deficiency of Interleukin-1 Receptor Antagonist Deteriorates Fatty Liver and Cholesterol Metabolism in Hypercholesterolemic Mice J. Biol. Chem., February 25, 2005; 280(8): 7002 - 7009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Kojma, K.-i. Hirata, T. Ishida, Y. Shimokawa, N. Inoue, S. Kawashima, T. Quertermous, and M. Yokoyama Endothelial Lipase Modulates Monocyte Adhesion to the Vessel Wall: A POTENTIAL ROLE IN INFLAMMATION J. Biol. Chem., December 24, 2004; 279(52): 54032 - 54038. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. C. Miller, C. J. Long, E. D. Bojilova, D. Marchadier, K. O. Badellino, N. Blanchard, I. V. Fuki, J. M. Glick, and D. J. Rader Role of N-linked glycosylation in the secretion and activity of endothelial lipase J. Lipid Res., November 1, 2004; 45(11): 2080 - 2087. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. C-W. Yu, C. David, S. Kadambi, A. Stahl, K.-I. Hirata, T. Ishida, T. Quertermous, A. D. Cooper, and S. Y. Choi Endothelial lipase is synthesized by hepatic and aorta endothelial cells and its expression is altered in apoE-deficient mice J. Lipid Res., September 1, 2004; 45(9): 1614 - 1623. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Khovidhunkit, M.-S. Kim, R. A. Memon, J. K. Shigenaga, A. H. Moser, K. R. Feingold, and C. Grunfeld Thematic review series: The Pathogenesis of Atherosclerosis. Effects of infection and inflammation on lipid and lipoprotein metabolism mechanisms and consequences to the host J. Lipid Res., July 1, 2004; 45(7): 1169 - 1196. [Abstract] [Full Text] [PDF]
|
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||